Cargando…

RASSF1A and the rs2073498 Cancer Associated SNP

RASSF1A is one of the most frequently inactivated tumor suppressors yet identified in human cancer. It is pro-apoptotic and appears to function as a scaffolding protein that interacts with a variety of other tumor suppressors to modulate their function. It can also complex with the Ras oncoprotein a...

Descripción completa

Detalles Bibliográficos
Autores principales: Donninger, Howard, Barnoud, Thibaut, Nelson, Nick, Kassler, Suzanna, Clark, Jennifer, Cummins, Timothy D., Powell, David W., Nyante, Sarah, Millikan, Robert C., Clark, Geoffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355887/
https://www.ncbi.nlm.nih.gov/pubmed/22649770
http://dx.doi.org/10.3389/fonc.2011.00054
_version_ 1782233453728628736
author Donninger, Howard
Barnoud, Thibaut
Nelson, Nick
Kassler, Suzanna
Clark, Jennifer
Cummins, Timothy D.
Powell, David W.
Nyante, Sarah
Millikan, Robert C.
Clark, Geoffrey J.
author_facet Donninger, Howard
Barnoud, Thibaut
Nelson, Nick
Kassler, Suzanna
Clark, Jennifer
Cummins, Timothy D.
Powell, David W.
Nyante, Sarah
Millikan, Robert C.
Clark, Geoffrey J.
author_sort Donninger, Howard
collection PubMed
description RASSF1A is one of the most frequently inactivated tumor suppressors yet identified in human cancer. It is pro-apoptotic and appears to function as a scaffolding protein that interacts with a variety of other tumor suppressors to modulate their function. It can also complex with the Ras oncoprotein and may serve to integrate pro-growth and pro-death signaling pathways. A SNP has been identified that is present in approximately 29% of European populations [rs2073498, A(133)S]. Several studies have now presented evidence that this SNP is associated with an enhanced risk of developing breast cancer. We have used a proteomics based approach to identify multiple differences in the pattern of protein/protein interactions mediated by the wild type compared to the SNP variant protein. We have also identified a significant difference in biological activity between wild type and SNP variant protein. However, we have found only a very modest association of the SNP with breast cancer predisposition.
format Online
Article
Text
id pubmed-3355887
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-33558872012-05-30 RASSF1A and the rs2073498 Cancer Associated SNP Donninger, Howard Barnoud, Thibaut Nelson, Nick Kassler, Suzanna Clark, Jennifer Cummins, Timothy D. Powell, David W. Nyante, Sarah Millikan, Robert C. Clark, Geoffrey J. Front Oncol Oncology RASSF1A is one of the most frequently inactivated tumor suppressors yet identified in human cancer. It is pro-apoptotic and appears to function as a scaffolding protein that interacts with a variety of other tumor suppressors to modulate their function. It can also complex with the Ras oncoprotein and may serve to integrate pro-growth and pro-death signaling pathways. A SNP has been identified that is present in approximately 29% of European populations [rs2073498, A(133)S]. Several studies have now presented evidence that this SNP is associated with an enhanced risk of developing breast cancer. We have used a proteomics based approach to identify multiple differences in the pattern of protein/protein interactions mediated by the wild type compared to the SNP variant protein. We have also identified a significant difference in biological activity between wild type and SNP variant protein. However, we have found only a very modest association of the SNP with breast cancer predisposition. Frontiers Research Foundation 2011-12-28 /pmc/articles/PMC3355887/ /pubmed/22649770 http://dx.doi.org/10.3389/fonc.2011.00054 Text en Copyright © 2011 Donninger, Barnoud, Nelson, Kassler, Clark, Cummins, Powell, Nyante, Millikan and Clark. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
spellingShingle Oncology
Donninger, Howard
Barnoud, Thibaut
Nelson, Nick
Kassler, Suzanna
Clark, Jennifer
Cummins, Timothy D.
Powell, David W.
Nyante, Sarah
Millikan, Robert C.
Clark, Geoffrey J.
RASSF1A and the rs2073498 Cancer Associated SNP
title RASSF1A and the rs2073498 Cancer Associated SNP
title_full RASSF1A and the rs2073498 Cancer Associated SNP
title_fullStr RASSF1A and the rs2073498 Cancer Associated SNP
title_full_unstemmed RASSF1A and the rs2073498 Cancer Associated SNP
title_short RASSF1A and the rs2073498 Cancer Associated SNP
title_sort rassf1a and the rs2073498 cancer associated snp
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355887/
https://www.ncbi.nlm.nih.gov/pubmed/22649770
http://dx.doi.org/10.3389/fonc.2011.00054
work_keys_str_mv AT donningerhoward rassf1aandthers2073498cancerassociatedsnp
AT barnoudthibaut rassf1aandthers2073498cancerassociatedsnp
AT nelsonnick rassf1aandthers2073498cancerassociatedsnp
AT kasslersuzanna rassf1aandthers2073498cancerassociatedsnp
AT clarkjennifer rassf1aandthers2073498cancerassociatedsnp
AT cumminstimothyd rassf1aandthers2073498cancerassociatedsnp
AT powelldavidw rassf1aandthers2073498cancerassociatedsnp
AT nyantesarah rassf1aandthers2073498cancerassociatedsnp
AT millikanrobertc rassf1aandthers2073498cancerassociatedsnp
AT clarkgeoffreyj rassf1aandthers2073498cancerassociatedsnp